InvestorsHub Logo
Followers 17
Posts 10848
Boards Moderated 0
Alias Born 03/11/2017

Re: None

Thursday, 08/17/2017 1:17:44 PM

Thursday, August 17, 2017 1:17:44 PM

Post# of 44784
Thursday...HC Wainwright Reaffirms “Buy” Rating for Pluristem Therapeutics


Pluristem Therapeutics, Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Thursday. They currently have a $3.50 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 194.12% from the stock’s previous close.


https://weekherald.com/2017/08/17/hc-wainwright-reaffirms-buy-rating-for-pluristem-therapeutics-inc-psti.html